Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (NASDAQ:OCS) disclosed a notification under managers' transactions relating to the vesting and settlement of RSUs previously granted to director Arshad Khanani. The notification references an RSU vest on 25 February 2026 and was published on 27 February 2026.

Key Figures

Registered resale shares: 494,259 shares Currently exercisable warrant: 59,310 shares Exercise price tranche 1: $12.17 +5 more

8 metrics

Registered resale shares 494,259 shares Form F-3 warrant share resale registration

Currently exercisable warrant 59,310 shares Portion of warrant presently exercisable

Exercise price tranche 1 $12.17 Exercise price for 361,011 warrant shares

Exercise price tranche 2 $18.64 Exercise price for 133,248 warrant shares

Max cash from warrant $6,877,246.59 Gross proceeds if all registered warrant shares exercised for cash

Underwritten offering size 4,691,358 shares at $20.25 Oct 31, 2025 prospectus supplement

Registered direct shares 740,740 shares at $20.25 Concurrent registered direct sale

Current share price $29.99 Pre-news trading level vs 52-week range $14–$30.68

Market Reality Check

Price: $29.41 Vol: Volume 358,431 vs 20-day ...

normal vol

$29.41 Last Close

Volume Volume 358,431 vs 20-day avg 330,687 (relative 1.08x) suggests only slightly elevated trading ahead of this administrative update. normal

Technical Shares at $29.99 are trading above the 200-day MA of $20.34 and sit about 2.25% below the 52-week high of $30.68, reflecting a strong pre-news uptrend.

Peers on Argus

Biotech peers show a mixed tape: ABUS, EYPT, and UPB are up, while QURE and TSHA...

1 Up 1 Down

Biotech peers show a mixed tape: ABUS, EYPT, and UPB are up, while QURE and TSHA are down. With OCS up 1.45% pre-news and peers moving in both directions, the backdrop points to stock-specific positioning rather than a clear sector-wide driver.

Historical Context

5 past events · Latest: Feb 18 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 18	Managerial transactions	Neutral	-0.6%	Disclosure of earnout share vesting and removal of related restrictions for four managers.
Feb 17	Executive appointment	Positive	+1.0%	Appointment of Chief Legal Officer ahead of key Phase 3 readouts and programs.
Jan 08	Pipeline showcase	Positive	+5.0%	Showcase of late-stage ophthalmology pipeline and upcoming pivotal milestones at JPM conference.
Jan 06	Regulatory milestone	Positive	+5.8%	FDA Breakthrough Therapy Designation for Privosegtor based on positive Phase 2 ACUITY data.
Jan 05	RSU vesting notice	Neutral	+5.8%	Administrative notification of RSU vesting and settlement for a director with no financial details.

Pattern Detected

Recent price reactions have generally aligned with news importance: clinical and regulatory milestones saw stronger positive moves, while routine governance and managerial transaction notices produced modest or mixed responses.

Recent Company History

Over the past months, Oculis has highlighted major clinical and financing milestones alongside routine governance updates. The Jan 6, 2026 Breakthrough Therapy Designation for Privosegtor and subsequent PIONEER program launch both triggered notable positive reactions. Equity raises in late 2025 were aimed at funding this late-stage pipeline. In parallel, the company has regularly disclosed managerial transactions and RSU vestings, including a similar director RSU notice on Jan 5, 2026. Today’s RSU-related PDMR notification fits into that pattern of administrative transparency rather than a new fundamental catalyst.

Regulatory & Risk Context

Active S-3 Shelf · $6,877,246.59

Shelf Active

Active S-3 Shelf Registration 2025-11-10

$6,877,246.59 registered capacity

An effective Form F-3 dated Nov 10, 2025 registers the resale of up to 494,259 warrant shares by a selling holder. Oculis is not selling securities under this prospectus and receives cash only if the warrant is exercised, up to $6,877,246.59 in gross proceeds. This structure points to potential secondary-market activity rather than primary dilution.

Market Pulse Summary

This announcement describes the vesting and settlement of RSUs previously granted to a company direc...

Analysis

This announcement describes the vesting and settlement of RSUs previously granted to a company director, continuing Oculis’s pattern of routine PDMR and compensation-related disclosures. It does not introduce new clinical or financial guidance. In context, the company recently advanced Privosegtor with Breakthrough Therapy Designation and funded development through equity offerings, and it maintains an F-3 registering up to 494,259 warrant shares with potential cash proceeds of $6.88M. Investors may watch for upcoming Phase 3 readouts and further regulatory updates as the key fundamental drivers.

Key Terms

RSUs

1 terms

RSUs financial

"relates to the vesting and settlement of RSUs previously granted to a director"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. Not financial advice.

ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Attachment

• Notification of managers' transaction - Arshad Khanani - 25 February 2026 RSU vest

FAQ

What did Oculis announce about the RSU vesting for director Arshad Khanani (OCS) on February 27, 2026?

Oculis announced the vesting and settlement of RSUs for director Arshad Khanani on 25 February 2026. According to Oculis, the notification documents the managers' transaction and confirms the prior RSU grant vested and settled as described.

Does the Oculis (OCS) notification on February 27, 2026) indicate any cash payment or stock issuance amount?

The notification reports vesting and settlement of RSUs but does not state cash amounts or share counts. According to Oculis, the attached notice simply documents the manager transaction without providing financial quantities.

When did the RSUs for Oculis director Arshad Khanani actually vest according to the Oculis (OCS) notice?

The RSUs for director Arshad Khanani vested on 25 February 2026, per the notification. According to Oculis, the published notice dated 27 February 2026 references that vest date for the settled RSUs.

Is the Oculis (OCS) managers' transaction notification on February 27, 2026 a regulatory filing or internal disclosure?

The notification is a managers' transaction disclosure documenting RSU vesting by a director. According to Oculis, it serves as a regulatory-style notification of the director's vested and settled equity award.

What should investors know about the impact of the RSU vesting notice for Oculis (OCS) dated February 27, 2026?

The notice records a director's RSU vesting and settlement but provides no financial metrics or guidance. According to Oculis, the disclosure is informational and does not specify amounts that would indicate material impact.